Paper Details

  1. Home
  2. Paper Details

Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.

Author: BertzRichard, ChangIh, ChienCaly, GraselaDennis, HannaGeorge J, HuangShu-Pang, KrystalMark, NettlesRichard E, RayNeelanjana, SchürmannDirk, StonierMichele, Wind-RotoloMegan, ZhuLi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

BMS-663068 is a prodrug that inhibits HIV-1 infection. In a study of 50 HIV-1-infected subjects, BMS-663068 was administered with or without ritonavir for 8 days. All regimens resulted in substantial decreases in plasma HIV-1 RNA levels and were generally well tolerated. Further clinical trials of BMS-663068 as part of combination antiretroviral therapy are warranted.
Paper Details　
Original Abstract of the Article :
BACKGROUND: BMS-663068 is a prodrug of the small-molecule inhibitor BMS-626529, which inhibits human immunodeficiency virus type 1 (HIV-1) infection by binding to gp120 and interfering with the attachment of virus to CD4+ T-cells. METHODS: Fifty HIV-1-infected subjects were randomized to 1 of 5 reg...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/infdis/jis432

データ提供：米国国立医学図書館（NLM）

A New Frontier in HIV Treatment: BMS-663068, an Oral Attachment Inhibitor

The fight against HIV, a formidable foe with a complex and ever-evolving nature, requires relentless innovation and research. This research explores the potential of a new drug, BMS-663068, an oral attachment inhibitor that targets HIV's ability to attach to healthy cells. Imagine a vast desert where a rogue oasis, the virus, seeks to invade and disrupt the delicate balance of life. This research investigates a new weapon to counter this invasion, preventing the virus from latching onto and infecting healthy cells.

BMS-663068: A Promising Weapon in the Fight Against HIV

The study revealed that BMS-663068, when administered orally, effectively reduced the levels of HIV in the blood of infected individuals. This drug's ability to block the virus's attachment to healthy cells, like a desert fortress blocking an invading caravan, is a promising breakthrough in the fight against HIV. The researchers believe that BMS-663068 has the potential to become a valuable addition to the arsenal of antiretroviral therapies available to HIV-positive individuals.

Hope for a Brighter Future: The Quest for Effective HIV Treatment

This research provides a glimmer of hope for the future of HIV treatment, offering a new avenue for controlling the virus and improving the quality of life for individuals living with HIV. The desert of HIV research is vast and unforgiving, but the relentless pursuit of effective therapies continues, fueled by the unwavering determination to conquer this challenging foe.

Dr.Camel's Conclusion

This study highlights the potential of BMS-663068 as a promising new weapon in the fight against HIV. This research is a reminder that the quest for effective HIV treatment is ongoing, with each new discovery paving the way for a brighter future for those affected by this challenging disease. We are hopeful that this research will lead to the development of more effective and safe therapies, offering hope for a world free from the devastating effects of HIV.

Date :
  1. Date Completed 2012-11-23
  2. Date Revised 2019-04-11
Further Info :

Pubmed ID

22896665

DOI: Digital Object Identifier

10.1093/infdis/jis432

Related Literature

Article Analysis
・Effects of fostemsavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.